Individual patient ’s behaviors , lack of social support , clinical or treatment and illness-related , and health system factors influenced psychotropic medication non-adherence .
Conclusion Psychotropic medication non-adherence was high .
It was influenced by various factors operating at different levels .
Background Major psychiatric disorders are growing public health concern that attributed 14 % of the global burden of diseases .
The management of major psychiatric disorders is challenging mainly due to medication non-adherence .
However , there is a paucity of summarized evidence on the prevalence of psychotropic medication non-adherence and associated factors .
Therefore , we aim ed to summarize existing primary studies ’ finding to determine the pooled prevalence and factors associated with psychotropic medication non-adherence .
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
BACKGROUND The electronic Schizophrenia Treatment Adherence Registry ( e-STAR ) is a prospect i ve , observational study of patients with schizophrenia design ed to evaluate long-term treatment outcomes in routine clinical practice . METHODS Parameters were assessed at baseline and at 3 month intervals for 2 years in patients initiated on risperidone long-acting injection ( RLAI ) ( n=1345 ) or a new oral antipsychotic ( AP ) ( n=277 ; 35.7 % and 36.5 % on risperidone and olanzapine , respectively ) in Spain .  Hospitalization prior to therapy was assessed by a retrospective chart review . RESULTS At 24 months , treatment retention ( 81.8 % for RLAI versus 63.4 % for oral APs , p<0.0001 ) and reduction in Clinical Global Impression Severity scores ( -1.14 for RLAI versus -0.94 for APs , p=0.0165 ) were significantly higher with RLAI . Compared to the pre-switch period , RLAI patients had greater reductions in the number ( reduction of 0.37 stays per patient versus 0.2 , p<0.05 ) and days ( 18.74 versus 13.02 , p<0.01 ) of hospitalizations at 24 months than oral AP patients . CONCLUSIONS This 2 year , prospect i ve , observational study showed that , compared to oral antipsychotics , RLAI was associated with better treatment retention , greater improvement in clinical symptoms and functioning , and greater reduction in hospital stays and days in hospital in patients with schizophrenia . Improved treatment adherence , increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia
Individual patient ’s behaviors , lack of social support , clinical or treatment and illness-related , and health system factors influenced psychotropic medication non-adherence .
Conclusion Psychotropic medication non-adherence was high .
It was influenced by various factors operating at different levels .
Background Major psychiatric disorders are growing public health concern that attributed 14 % of the global burden of diseases .
The management of major psychiatric disorders is challenging mainly due to medication non-adherence .
However , there is a paucity of summarized evidence on the prevalence of psychotropic medication non-adherence and associated factors .
Therefore , we aim ed to summarize existing primary studies ’ finding to determine the pooled prevalence and factors associated with psychotropic medication non-adherence .